Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza

HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.

Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?

Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is favoured by institutional owners who hold 62% of the company

Key Insights Significantly high institutional ownership implies Amphastar Pharmaceuticals' stock price is sensitive to...

Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

The Cream Of The Crop: 5 Biotech Stocks That Outrank 98% Of All Stocks

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

2 Stocks to Buy Now After Powell Flips the Narrative... Again

Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely

U.S. FDA approves Amphastar Pharma's nasal spray for opioid overdose

Amphastar Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its nasal spray for emergency treatment of known or suspected opioid overdose.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device.

FDA approves Amphastar Pharma`s naloxone hydrochloride nasal spray 4mg

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.